GIPL Global Innovative Platforms Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1837774 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-20.9%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-361.7%
Net margin-361.7%
FCF margin—
EBITDA margin—
Returns
ROE-190.0%
ROA-180.9%
ROIC (approx.)-395.6%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets1.4%
Debt / equity0.00x
Current ratio34.73x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-91.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $50,700 | $106,500 | $30,000 | $0 | $0 | $0 | — | $0 |
| R&D expense | $3,380 | $1,825 | $10,681 | $362,099 | $8,962 | $3,541 | $34,250 | — |
| SG&A expense | — | — | $68,748 | -$148,216 | $211,818 | $151,351 | $86,217 | $76,482 |
| Operating income | -$241,611 | -$151,386 | -$49,429 | -$234,616 | -$211,818 | -$151,351 | -$120,467 | -$76,482 |
| Pretax income | -$241,611 | -$151,386 | -$49,429 | -$234,616 | -$211,818 | -$151,351 | -$120,467 | -$76,482 |
| Income tax | $0 | $0 | — | — | $0 | $0 | — | $0 |
| Net income | -$241,611 | -$151,386 | -$49,429 | -$234,616 | -$211,818 | -$151,351 | -$120,467 | -$76,482 |
| EBITDA | -$229,759 | -$138,225 | -$44,416 | — | -$211,818 | — | — | — |
| EPS (basic) | -0.01 | -0.00 | -0.00 | — | -0.01 | -0.00 | -0.00 | — |
| EPS (diluted) | — | — | -0.00 | — | -0.01 | -0.00 | -0.00 | — |
| Weighted avg. shares (diluted) | 0 | 0 | 44.54M | — | 0 | 0 | 35.75M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $244,235 | $327,270 | $49,004 | $17,828 | $198,137 | $155,909 | $148,459 | $15 |
| Receivables | $14,700 | $18,000 | — | $0 | — | — | — | — |
| Current assets | $270,609 | $366,570 | $54,516 | $199,275 | $209,160 | $166,932 | $148,459 | $15 |
| PP&E, net | $264,870 | $221,606 | $170,435 | $0 | $0 | $0 | $0 | $0 |
| Intangibles | $3,782 | $3,782 | — | $0 | — | — | — | — |
| Total assets | $539,261 | $591,958 | $224,951 | $199,275 | $209,160 | $166,932 | $148,459 | $15 |
| Current liabilities | $7,791 | $2,284 | $65,784 | $11,609 | $27,823 | $3,229 | $14,407 | $33,153 |
| Short-term debt | $5,616 | $0 | — | $1,500 | — | — | — | — |
| Total liabilities | $7,791 | $2,284 | $65,784 | $11,609 | $27,823 | $3,229 | $14,407 | $33,153 |
| Shareholders' equity | $531,470 | $589,674 | $159,567 | $187,666 | $181,337 | $163,703 | $134,051 | -$33,138 |
| Shares outstanding | 49.75M | 48.68M | 45.98M | 44.48M | 42.18M | 39.11M | 37.30M | 33.75M |
| Cash flow statement | ||||||||
| Operating cash flow | -$133,565 | -$149,473 | $12,676 | -$64,861 | -$184,273 | -$173,549 | -$138,057 | -$59,713 |
| Capital expenditure | $55,116 | — | — | — | $0 | — | — | — |
| Free cash flow | -$188,681 | — | — | — | -$184,273 | — | — | — |
| Investing cash flow | -$55,116 | — | — | -$175,448 | $0 | — | — | $0 |
| Financing cash flow | $105,646 | $495,854 | $18,500 | $60,000 | $226,501 | $180,999 | $286,501 | $49,582 |
| Depreciation & amortization | $11,852 | $13,161 | $5,013 | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.